Novo Nordisk As operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novo Nordisk As with three other
companies in this sector in the United States:
Teva Pharmaceutical Industries Limited
sales of $19.65 billion
of which 49%
was Generic Madicines),
of which 13%
was Anda Distribution), and
Bristol-Myers Squibb Company
of which 100%
During the year ended December of 2015, sales at
Novo Nordisk As were $15.96 billion.
a very small
increase of 1.4%
versus 2014, when the company's sales were $15.73 billion.
This was the fifth consecutive year of sales increases at Novo Nordisk As
(and since 2010, sales have increased a total of 48%).
Sales of Diabetes Care saw an increase
2.1% in 2015, from
$12.40 billion to $12.66 billion.
Not all segments of Novo Nordisk As experienced an increase in sales in 2015:
sales of Biopharmaceuticals fell 1.0% to $3.30 billion.